Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ. Muriel C, et al. Among authors: esteban e. Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0. Clin Transl Oncol. 2010. PMID: 20709657
Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Esteban E, Modollel A, González de Sande L, Palacio I, Muñiz I, Fernández Y, Corral N, Fra J, Sala M, Vieitez JM, Estrada E, Lacave AJ; Grupo Oncológico del Norte de España. Esteban E, et al. Breast Cancer Res Treat. 2003 Aug;80(3):257-65. doi: 10.1023/a:1024985309383. Breast Cancer Res Treat. 2003. PMID: 14503798 Clinical Trial.
Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.
Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON). Esteban E, et al. Invest New Drugs. 2006 May;24(3):241-8. doi: 10.1007/s10637-005-2478-z. Invest New Drugs. 2006. PMID: 16096704 Clinical Trial.
Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.
Esteban E, de Sande JL, Villanueva N, Corral N, Muñiz I, Vieitez JM, Fra J, Fernández Y, Estrada E, Fernandez JL, Luque M, Jimenez P, Mareque B, Capellan M, Buesa JM, Lacave AJ. Esteban E, et al. Lung Cancer. 2007 Feb;55(2):173-80. doi: 10.1016/j.lungcan.2006.09.021. Epub 2006 Oct 27. Lung Cancer. 2007. PMID: 17070962 Clinical Trial.
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Esteban E, Villanueva N, Muñiz I, Fernández Y, Fra J, Luque M, Jiménez P, Llorente B, Capelan M, Vieitez JM, Estrada E, Buesa JM, Jiménez-Lacave A. Esteban E, et al. Invest New Drugs. 2008 Feb;26(1):67-74. doi: 10.1007/s10637-007-9073-4. Epub 2007 Sep 5. Invest New Drugs. 2008. PMID: 17805486 Clinical Trial.
432 results